Laboratory analysis of CDH1 missense mutation
Laboratory analysis of CDH1 missense mutation
Why the ADAURA study is a big step forward for NSCLC
CheckMate 459: Long-term survival outcomes with nivolumab versus sorafenib as first-line treatment in aHCC
Novel immunotherapy approaches for small cell lung cancer
Renal cell cancer: Highlights from ASCO 2020
HERO: Relugolix versus leuprolide acetate for advanced prostate cancer
MASTER trial updates: Dara-KRd induction, autologous transplantation and MRD response-adapted consolidation in NDMM
UKALL2011: Treatment with a tyrosine kinase inhibitor improves outcomes for patients with acute lymphoblastic leukaemia and an ABL-class fusion
Phase I/II results: First-line NALIRIFOX in patients with pancreatic ductal adenocarcinoma
Long-term disease control in multiple myeloma by in-class transitioning: A community-based study
Venetoclax plus navitoclax in R/R ALL and lymphoblastic lymphoma
The future of PARP inhibitors in prostate cancer